Allarity Therapeutics, Inc.

ALLR

US0167444019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.38 ^USD	-5.48%		-2.82%	-87.48%

Apr. 15	Top Premarket Gainers	MT
Apr. 12	Top Premarket Gainers	MT

Allarity Therapeutics, Inc. Announces Termination of Marie Foegh as Chief Medical Officer

March 04, 2024 at 04:06 pm EST

On February 28, 2024, Allarity Therapeutics, Inc. terminated the employment of Marie Foegh, M.D., the company?s Chief Medical Officer. Ms. Foegh?s last day of employment was February 29, 2024.

Latest news about Allarity Therapeutics, Inc.

Top Premarket Gainers	Apr. 15	MT
Top Premarket Gainers	Apr. 12	MT
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split	Apr. 04	MT
Transcript : Allarity Therapeutics, Inc. - Shareholder/Analyst Call	Apr. 01
Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer	Mar. 27	CI
Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding	Mar. 13	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Allarity Therapeutics, Inc. Announces Termination of Marie Foegh as Chief Medical Officer	Mar. 04	CI
Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP	Feb. 12	CI
Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board	Feb. 01	CI
Allarity Therapeutics, Inc. announced that it expects to receive $0.8 million in funding from 3i, LP	Jan. 17	CI
Allarity Therapeutics Announces Executive Changes	Dec. 12	CI
Allarity Therapeutics, Inc. Announces Chief Executive Officer Changes	Dec. 11	CI
Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic	Dec. 05	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Certain Series C Preferred Stock of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Series A Preferred Stock of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Warrants of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Options of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Certain Common Stock of Allarity Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 9-OCT-2023.	23-10-08	CI
Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology	23-09-14	CI
Top Premarket Gainers	23-08-31	MT
Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic for Dovitinib in the Peer-Reviewed Journal PLOS ONE	23-08-30	CI
Allarity Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Allarity Therapeutics, Inc. Announces Board Changes	23-08-11	CI

Chart Allarity Therapeutics, Inc.

Duration

Period

More charts

Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the intellectual property rights to develop, use and market stenoparib. Its DRP companion diagnostic platform is a predictive biomarker technology that employs complex systems biology and bio-analytics with a clinical relevance filter to bridge the gap between in vitro cancer cell responsiveness to a given therapeutic candidate and in vivo likelihood of actual patient benefit from that therapeutic candidate. Its DRP companion diagnostic platform provides a gene expression signature, which reveals whether a specific tumor in a specific patient is likely to respond to one of its therapeutic candidates.

Sector

Biotechnology & Medical Research

Calendar

2024-05-23 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.38

Average target price

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ALLARITY THERAPEUTICS, INC.	-87.48%	426K
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.98%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.21%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs